NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think DocLogic is correct. I was recently nosing around some of the same material in addition to other articles. I found it telling that about 1/3 of the average GBM IV population falls within the mesenchymal subgroup. If you add this to the fact that those with tumor progression or pseudo- progression after chemo/radiation but before treatment are not included in the main DCVAX-L phase III study, the chance for early termination is much higher. (Note: Further research into the very latest studies on pseudo progression demonstrate those patients fair about as well as the post/chemo non-true progression group when surgery/chemo/radiation are the sole treatments). Anyway, the high responding mesenchymal subgroup will compound the results when added to the fact that patients whose tumors are stable (albeit temporarily), after surgery/chemo/radiation, and at the time DCVAX-L treatment is initiated also respond much better -- in historical DCVAX data.


In other words DCVAX-L response is magnified by:

(Mesenchymal group) + (post-surgery/chemo/radiation group with no tumor progress when DCVAX-L trial is initiated) - (patient population with tumor progress after surgery/chemo/radiation) = higher chance for statistical significance in the trial population.

Or


High responder + high responder - lower responder = Increased chance for success.